Article
Original Article

Dr. Shruthi Raveendran*1 , Dr. Shruthi S*2 , Dr. Nisha K J*3 , Dr. Sanjeela Guru*4 , Dr. Parichaya Batra*5 , Dr. Anjana Suresh U*6 

1, 6: Post Graduate Student, Department of periodontics,Vydehi Institute of Dental Sciences and Research Centre, Bangalore. 2, 4: Reader, Department of periodontics, Vydehi Institute of Dental Sciences and Research Centre, Bangalore 3: Prof & HOD, Department of periodontics, Vydehi Institute of Dental Sciences and Research Centre, Bangalore 5: Senior Lecturer, Department of periodontics, Vydehi Institute of Dental Sciences and Research Centre, Bangalore

Address for correspondence:

Dr. Nisha K.J.

Prof & amp; HOD, Department of Periodontics together, Vydehi institute of dental sciences and research centre, Bangalore. Email id- nisharejath@gmail.com

Year: 2019, Volume: 11, Issue: 2, Page no. 2-10, DOI: 10.26715/rjds.11_2_2
Views: 1482, Downloads: 44
Licensing Information:
CC BY NC 4.0 ICON
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0.
Abstract

Introduction: Periodontitis is a multifactorial disease, which, when not adequately treated, is followed with progressive attachment loss which leads to tooth mobility and eventually tooth loss. Periodontal regenerative surgery aims to regenerate and reconstruct the lost periodontal tissue. Regeneration with novabone putty has shown to be effective in reducing probing pocket depth, gain in clinical attachment level and increase in horizontal bone level.

Aim: This interventional clinical trial was to evaluate the osseous regenerative potential of a calcium phosphosilicate bioactive glass NOVABONE TM in the treatment of horizontal bone defects.

Materials and method: A total of 20 sites with horizontal bone defect was treated with open flap debridement with intra marrow penetration and novabone putty. Statistical analysis: Plaque index, gingival index and radiographic determination were analysed by paired t test. Probing pocket depth and clinical attachment levels were analysed by Wilcoxon Signed Ranks Test.

Result: There was significant reduction seen in plaque index, gingival index, probing pocket depth and radiographic crestal level when compared between baseline and 12 months respectively (2.48 ± 0.44, 2.92 ± 0.39, 6.80 ± 0.89, 8.29 ± 0.87) and (1.89 ± 0.42, 1.92± 0.51, 3.00± 0.67, 5.48 ± 0.89) and significant gain in clinical attachment level from 4.40 ± 0.96 to 1.20 ± 0.91.

Conclusion: The present study showed novabone putty significantly improved the clinical parameters in horizontal bone defects.

<p><strong>Introduction: </strong>Periodontitis is a multifactorial disease, which, when not adequately treated, is followed with progressive attachment loss which leads to tooth mobility and eventually tooth loss. Periodontal regenerative surgery aims to regenerate and reconstruct the lost periodontal tissue. Regeneration with novabone putty has shown to be effective in reducing probing pocket depth, gain in clinical attachment level and increase in horizontal bone level.</p> <p><strong>Aim: </strong>This interventional clinical trial was to evaluate the osseous regenerative potential of a calcium phosphosilicate bioactive glass NOVABONE TM in the treatment of horizontal bone defects.</p> <p><strong>Materials and method:</strong> A total of 20 sites with horizontal bone defect was treated with open flap debridement with intra marrow penetration and novabone putty. Statistical analysis: Plaque index, gingival index and radiographic determination were analysed by paired t test. Probing pocket depth and clinical attachment levels were analysed by Wilcoxon Signed Ranks Test.</p> <p><strong>Result: </strong>There was significant reduction seen in plaque index, gingival index, probing pocket depth and radiographic crestal level when compared between baseline and 12 months respectively (2.48 &plusmn; 0.44, 2.92 &plusmn; 0.39, 6.80 &plusmn; 0.89, 8.29 &plusmn; 0.87) and (1.89 &plusmn; 0.42, 1.92&plusmn; 0.51, 3.00&plusmn; 0.67, 5.48 &plusmn; 0.89) and significant gain in clinical attachment level from 4.40 &plusmn; 0.96 to 1.20 &plusmn; 0.91.</p> <p><strong>Conclusion: </strong>The present study showed novabone putty significantly improved the clinical parameters in horizontal bone defects.</p>
Keywords
Periodontitis, osteoconduction, regeneration, novabone putty, horizontal alveolar bone loss.
Downloads
  • 1
    FullTextPDF
Article

INTRODUCTION

Periodontitis is a multifactorial disease, which, when not adequately treated, is followed by progressive attachment loss which leads to tooth mobility and eventually tooth loss. If managed appropriately, involving a systematic and thorough control of the periodontal inflammation, periodontally affected teeth can be retained for long-term, at limited costs, even in cases where bone loss (BL) is advanced. Alteration and elimination of microbial aetiology and containing risk factors determines the goal of periodontal therapy which ultimately leads to preservation of dentition in a state of health, comfort and function with appropriate aesthetics.1 It also aims at regeneration of periodontal attachment apparatus which is lost, whenever indicated, thereby restoring the lost function and structure of tissues.

The end result of periodontal regenerative therapies are the alveolar bone repair and new cementum formation with collagen fibres inserted onto the root surfaces which were involved by the periodontal disease.2 The progression of periodontal disease can be halted by the conventional treatment modalities like scaling and root planing which have been proven to be effective. Elimination of pocket depths and regeneration of new attachment apparatus leading to the periodontal unit reconstruction within the existing normal physiological limits remains to be the aim of periodontal surgery, in particular regenerative periodontal surgery.

Literature states that the treatment modalities for vertical bone loss is around 96.8 % in spite of its prevalence being as less as 7.8%. Whereas horizontal bone loss with a maximum prevalence of 92.2% gets very little attention with treatment modalities being 3.2% only.3

The treatment option for horizontal defects remains to be the open flap debridement. Of lately there has been a quest among the periodontists to explore horizontal defect regeneration with the advent of various biomaterials and biologic approaches.

Regenerative therapy is attempted commonly by the use of various bone grafts. Calcium phosphosilicate bioactive glass, developed by Hench and West in the late 1960s, because of its reported advantages of forming a strong bond with living tissues both bone and soft tissue and its modulus of elasticity being similar to that of bone has gained a place as a good periodontic regenerative material .4,5

The good handling, homeostatic and osteoconductive properties of NovaBoneTM putty makes it one of the promising newer bone graft material. The other property of the graft to act as an epithelial barrier, retarding the epithelial down growth, obliviates the use an additional membrane.4

NovaBoneTM is a commercially available bioactive glass intended for filling surgical or traumatic bone gaps.4 Its composition is 45% silica dioxide, 45% sodium oxide, 5% calcium, and 5% phosphate.5 NovaBoneTM, a secondgeneration NovaBoneTM product, has two components: a slowly absorbing, melt-derived calcium phosphosilicate bioglass and a more rapidly absorbed solution-gelation calcium phosphosilicate component. The latter is more rapidly absorbed, leaving more space for bone infiltration in the interstices between the more slowly absorbed melt-derived component. 6 NovaBoneTM thus acts as a scaffold for the ingrowth of new bone and is substantially resorbed within 6 months.

The binder is absorbed to permit tissue infiltration between the bioglass particles on implantation. During the healing process the new bone tissue replaces the particles which are absorbed slowly. This osteostimulation results in new bone formation throughout the grafted site at rates faster than those seen with other synthetic graft materials.7

Literature regarding the use of NovaBoneTM putty in periodontal regenerative approaches in the management of horizontal defects were lacking. The aim of this interventional clinical trial was to evaluate the osseous regenerative potential of a calcium phosphosilicate bioactive glass - NovaBone TM in the treatment of horizontal bone defects.

Materials and methods

Patients visiting the Department of Periodontics, Vydehi Institute of Dental Sciences and Research Centre, Bangalore were selected based on the following inclusion criteria: age group between 20-60 years, systemically healthy patients with chronic periodontitis clinically diagnosed based on American Academy Periodontology (1999) classification having clinical attachment loss (CAL) ≥ 3mm in 30% of the sites and probing pocket depth (PPD) ≥ 5 mm with at least 6 teeth, presence of horizontal bone loss ≥ 6mm measuring from cementoenamel junction (CEJ) radiographically. Patients were excluded if medically compromised, teeth with grade III mobility, patients who underwent periodontal surgery in the last 1year, smokers, pregnant and lactating women. The study was approved by the institutional ethical committee (204/2019).

Study design

A total of 20 sites with horizontal bone defects in 5 patients satisfying the above mentioned criteria were included in the study. The nature of the study, the need for surgery and the outcome of it was explained to the patients, following which a verbal and written consent was obtained. The sample size was calculated based on data from previous literature using software SPSS 23.0 version. Clinical parameters

A single examiner performed all the investigations required and all the parameters were noted at baseline and 12 months. Parameters noted were gingival index (GI) (Loe & Silness, 1963)8 plaque index (PI) (Silness & Loe, 1964)9, probing pocket depth and clinical attachment level the measurements were made using surgical stent (Figure A) for reproducibility.

Radiographic assessment

Radiographic evaluation was carried out using Radiovisiography (RVG) taken at baseline and 12 months. RVG was obtained in a standardised exposure set up. RVG SOPIX2 ACE and CARESTREAM CS2100 X-ray unit operated at 60 Kvp and 7mA with a radiation exposure of 0.250 milliseconds. The sensor was covered with plastic sleeves and for each patient a new plastic cover was used hence ensuring optimum hygiene. The system we used in our study contained a charged coupled device or CCD sensor. RVG was obtained at baseline and 12 months follow up visit. To standardise the measurement the initial reference point was taken from Cementoenamel junction (CEJ) up to the crest of alveolar bone (CAB). A line is drawn from the CEJ of one tooth to the CEJ of adjacent tooth, the same way another parallel line is drawn from CAB joining adjacent 2 teeth. The midpoint from the CEJ line to the midpoint of CAB line is taken (Figure F). After obtaining the baseline and 12 months postoperative images (Figure G), the images was transferred into Digimizer image analysis software and all the images were resized to width of 600 pixels and height of 400 pixels which standardize the image size and the measurements were obtained and transferred to the master chart.

Presurgical therapy

Full mouth scaling and root planing was done. 

Oral hygiene instructions were given. Patients were recalled after 8 weeks for revaluation. Sites demonstrating >6mm of probing pocket depth during follow up after phase I therapy were considered for surgical management.

Surgical protocol

All the surgeries were done by a single examiner. The selected patients were subjected to the following surgical protocol. The operated site was anaesthetised with 2% local anaesthesia with 1:200000 adrenaline. No 15 blade was used to give crevicular incision and full thickness mucoperiosteal flap was reflected and the defect was debrided to remove granulation tissue using area specific Hu-Friedy Gracey curettes. Saline irrigation was done. Contrangled micromotor handpiece and a round carbide bur of 1 mm diameter was used to make intra marrow penetration in the interdental area (Figure B). The required amount of NovaBone putty was taken and placed in the defect area (Figure C). Vertical mattress sutures were placed using 3-0 silk suture (Figure D). Periodontal dressing was placed and post-operative instructions were given.

Post-operative

care All the patients were prescribed cap amoxicillin 500mg thrice daily for 5 days and combination of Tab Diclofenac Sodium 50mg with Tab Paracetamol 325mg twice daily for 3 days 0.2% chlorhexidine gluconate oral rinse was given twice daily for 15 days. Patients reported for suture removal post 10 days. All the patients were recalled once in every two months intervals up to 12 months for plaque removal and reinforcement of oral hygiene instructions.

Statistical analysis

Statistical analysis was done using a SPSS software 23.0 version. The analyses values were represented by mean and standard deviation. Parameters were analysed at baseline and 12 months. Plaque index, gingival index and radiographic determination were analysed by paired t test. Probing pocket depth and clinical attachment levels were analysed by Wilcoxon Signed Rank Test.

Results

A total of 20 sites of horizontal bone loss were treated with NovaBoneTM putty. All treated sites showed uneventful healing.

All parameters were assessed at baseline and 12 months. There was statistically significant reduction in plaque and gingival index from baseline to 12 months with P value <0.001. There was a reduction in probing pocket depth from baseline to 12 months and the difference was statistically significant. A great gain in clinical attachment level was found from baseline to 12 months, which was statistically significant. There was statistically significant gain in the defect fill from baseline to 12 months with P value <0.001 (Table I).

DISCUSSION

Destruction of bone, periodontal ligament and cementum are the end result of Periodontal diseases. Hence regeneration of these lost tissues remains to be the ultimate goal of periodontal therapy.10 In spite of numerous treatment modalities available currently, we clinicians continue to seek for regenerative therapies that are less technique sensitive and leads to faster tissue regeneration.

Horizontal bone loss remains to be the most commonly encountered clinical situation whose regeneration poses a major challenge to the periodontists.

Nova Bone TM putty is a new next generation calcium phosphosillicate bone graft material built from a bioactive glass platform with additives. The major advantage of this material is its improved handling and efficacy besides being osteostimulative and osteoconductive,11 hence in this present study this material was used to evaluate its regenerative potential in horizontal bone defects.

Our findings were similar to the clinical and radiographic findings observed by Rosamma et al12 where the efficacy of autologous platelet rich fibrin in horizontal alveolar bony defect was evaluated. Our clinical results were in accordance to the few previous studies which aimed at regenerating horizontal bone loss.13,14,15,16

In this study intra marrow penetration was done in the interdental area with round carbide bur mainly to enhance bone regeneration capacity. This procedure was done to expose cancellous bone which indeed cause bleeding, through which regenerative cells, bone morphogenetic proteins and growth factors can readily interact with the artificial bone graft material and accelerate the new bone formation process.17,18 Crea et al. evaluated the efficacy of intramarrow penetration along with open flap debridement which resulted with gain in clinical attachment level, reduction in probing depth and bone fill seen in radiographic assessment.19

As digital radiographs are more accurate in measurements than conventional radiographs while measuring alveolar bone loss,20,21 here we used RVG for a more accurate pre and post radiographic comparison.

The limitation of the present study was that it had only one group in contrast to other studies, hence necessitating future studies with a comparative group with standard protocols. The other limitation of this study included assessment of periodontal regeneration using only clinical and radiographic parameters.

True periodontal regeneration can only be assessed in histological sections.22,23 Due to ethical reasons it could not be done in the present study.

Studies have focused on the regenerative potential of NovaBoneTM putty in intrabony defects24 and furcation area.25 Materials like PRF12 and enamel matrix proteins16 have also been tried in the regeneration of horizontal alveolar bone loss. There is no study done till date to the best of our knowledge to check the evaluation of regenerative potential of NovaBoneTM putty in horizontal alveolar bone defect, hence making this study a novel treatment option and also increasing its research potential in this area.

Conclusion

Treatment modalities in horizontal defect is minimal and the present study has shown that novabone putty significantly improved the clinical and radiographic parameters in horizontal bone defects within the limitations, hence further studies including larger sample size are recommended. 

Supporting Files
No Pictures
References
  1. American Academy of Periodontology. Comprehensive Periodontal Therapy: A Statement by the American Academy of Periodontology. J Periodontol. 2011 Jul;82(7):943-9. doi: 10.1902/ jop.2011.117001.
  2. Ramseier CA, Rasperini G, Batia S, and Giannobile WV. Advanced regenerative technologies for periodontal tissue repair. Periodontol 2000. 2012; 59(1):185–202.
  3. Jayakumar A, Rohini S, Naveen A, Haritha A, Reddy K. Horizontal alveolar bone loss: A periodontal orphan. J Indian Soc Periodontol 2010;14:181‑5.
  4. FDA . NovaBoneAR marketing approval. In: In: Services HaH, editor. 2004.
  5. Cho Y R, Gosain A K. Biomaterials in craniofacial reconstruction. ClinPlast Surg. 2002;31:377–385.
  6. FDA . NovaBone Putty marketing approval. In: In: Services HaH, editor. 2006
  7. Wang Z, Lu B, Chen L, Chang J. Evaluation of an osteostimulative putty in the sheep spine. J Mater Sci Mater Med 2011;22:185-91.
  8. Loe H, Silness J. Periodontal disease in pregnancy. I. Prevalence and severity. Acta Odontol Scand 1963;21:533‑51.
  9. Silness J, Loe H. Periodontal disease in pregnancy. II. Correlation between oral hygiene and periodontal condtion. Acta Odontol Scand 1964;22:121‑35.
  10. Siaili M, Chatzopoulou D, Gillam DG. An overview of periodontal regenerative procedures for the general dental practitioner. Saudi Dent J. 2018;30:26-37.
  11. Papapanou PN, Tonetti MS. Diagnosis and epidemiology of periodontal osseous lesions. Periodontol 2000. 2000;22:8-21
  12. Goldman HM, Cohen DW. The infrabony pocket: Classification and treatment. J Periodontol 1958;29:272.
  13. Papapanou PN, Wennström JL, Gröndahl K. Periodontal status in relation to age and tooth type. A cross-sectional radiographic study. J Clin Periodontol 1988;15:469-78.
  14. Papapanou PN, Wennström JL. A 10-year retrospective study of periodontal disease progression. Clinical characteristics of subjects with pronounced and minimal disease development. J Clin Periodontol 1990;17:78-84
  15. Umashankar DN, Kumar KS, Kumar RM, Srinath N, Patil C. Efficacy of calcium phosphosilicate as graft material in bony defects. Int J Oral Care Res 2018;6(1):17-23
  16. Joseph RV, Sam G, Amol NV. Clinical evaluation of autologous platelet rich fibrin in horizontal alveolar bony defects. Journal of Clinical and Diagnostic Research 2014;8(11): ZC43-ZC47
  17. Stahl SS, Froum SJ. Healing of human suprabony lesions treated with guided tissue regeneration and coronally anchored flaps. Case reports. J Clin Periodontol 1991;18:69-74.
  18. Kotschy P, Munzker R. New dimensions in guided tissue regeneration treatment modalities for profound marginal periodontitis. Int J Periodontics Restorative Dent.1995;15:284-97.
  19. Kassolis JD, Bowers GM. Supracrestal bone regeneration: a pilot study. Int J Periodontics Restorative Dent 1999;19:131-39.
  20. Yilmaz S, Kuru B, Altuna-Kirac E. Enamel matrix proteins in the treatment of periodontal sites with horizontal type of bone loss. J Clin Periodontol 2003;30:197- 206.
  21. Buser D, Bragger U, Lang NP, Nyman S. Regeneration and enlargement of jaw bone using guided tissue regeneration. Clin Oral Implants Res 1990;1:22–32.
  22. Simion M, Jovanovic SA, Trisi P, Scarano A, Piattelli A. Vertical ridge augmentation around dental implants using a membrane technique and autogenous bone or allografts in humans. Int J Periodontics Restorative Dent 1998;18:8–23.
  23. Crea A, Deli G, Littarru C, Lajolo C, Orgeas GV, Tatakis DN, et al. Intrabony defects, open-flap debridement, and decortication: A randomized clinical trial. J Periodontol 2014;85:34-42.
  24. Sculean A, Nikolidakis D, Nikou G, Ivanovic A, Chapple IL, Stavropoulos A. Biomaterials for promoting periodontal regeneration in human intrabony defects: A systematic review. Periodontol 2000. 2015;68(1):182–216.
  25. Debnath K, Chatterjee A. Treatment of horizontal defect with and without platelet-rich fibrin matrix: A randomized comparative clinical study. J Indian Soc Periodontol 2018;22:406-13.
  26. Bowers G, Chadroff B, Carnevale R, Mellonig J, Corio R, Emerson J, Stevens M, Romberg E. Histologic evaluation of new human attachment apparatus formation
  27. Gottlow J, Nyman S, Lindhe J, Karring T, Wennstrom J. New attachment formation in the human periodontium by guided tissue regeneration. Case reports. J Clin Periodontol 1986;13:604-16.
  28. Bembi NN, Bembi S, Mago J, Baweja GK, Baweja PS. Comparative Evaluation of Bioactive Synthetic NovaBone Putty and Calcified Algae-derived Porous Hydroxyapatite Bone Grafts for the Treatment of Intrabony Defects. Int J Clin Pediatr Dent 2016;9(4):285-290
  29. Gupta AV, Bains VK, Singh GP, Jhingran R. Clinical and cone beam computed tomography comparison of NovaBone Dental Putty and PerioGlas in the treatment of mandibular Class II furcations. Indian J Dent Res 2014;25:166- 173 
We use and utilize cookies and other similar technologies necessary to understand, optimize, and improve visitor's experience in our site. By continuing to use our site you agree to our Cookies, Privacy and Terms of Use Policies.